1. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nature Reviews Genetics. 2003; 4(5): 346-58. [
DOI:10.1038/nrg1066]
2. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Current gene therapy. 2003; 3(6): 545-65. [
DOI:10.2174/1566523034578131]
3. Lundstrom K, Boulikas T. Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technology in cancer research & treatment. 2003; 2(5): 471-85. [
DOI:10.1177/153303460300200513]
4. Zhou X, Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1994; 1189(2): 195-203. [
DOI:10.1016/0005-2736(94)90066-3]
5. Nabel EG, Gordon D, Yang Z-Y, Xu L, San H, Plautz GE, et al. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Human gene therapy. 1992; 3(6): 649-56. [
DOI:10.1089/hum.1992.3.6-649]
6. Yang JP, Huang L. Time-dependent maturation of cationic liposome-DNA complex for serum resistance. Gene therapy. 1998; 5(3): 380-7. [
DOI:10.1038/sj.gt.3300596]
7. Schmidt-Wolf GD, Schmidt-Wolf IG. Non-viral and hybrid vectors in human gene therapy: an update. Trends in molecular medicine. 2003; 9(2): 67-72. [
DOI:10.1016/S1471-4914(03)00005-4]
8. Kim TK, Eberwine JH. Mammalian cell transfection: the present and the future. Analytical and Bioanalytical Chemistry. 2010; 397: 3173-3178. [
DOI:10.1007/s00216-010-3821-6]
9. Labat-Moleur F, Steffan AM, Brisson C, Perron H, Feugeas O, Furstenberger P, et al. An electron microscopy study into the mechanism of gene transfer with lipopolyamines. Gene therapy. 1996; 3(11): 1010-1017.
10. Maurisse R, De Semir D, Emamekhoo H, Bedayat B, Abdolmohammadi A, Parsi H, et al. Comparative transfection of DNA into primary and transformed mammalian cells from different lineages. BMC Biotechnology. 2010; 10:1. doi: 10.1186/1472-6750-10-9. [
DOI:10.1186/1472-6750-10-9]
11. Avci-Adali M, Behring A, Keller T, Krajewski S, Schlensak C, Wendel HP. Optimized conditions for successful transfection of human endothelial cells with in vitro synthesized and modified mRNA for induction of protein expression. Journal of biological engineering. 2014; 8(1): 8. doi: 10.1186/1754-1611-8-8. [
DOI:10.1186/1754-1611-8-8]
12. Morrey ME, Anderson PA, Chambers G, Paul R. Optimizing nonviral-mediated transfection of human intervertebral disc chondrocytes. Spine J. 2008; 8(5): 796-803. [
DOI:10.1016/j.spinee.2007.05.010]
13. Ward CM, Stern PL. The Human Cytomegalovirus ImmediateâEarly Promoter is Transcriptionally Active in Undifferentiated Mouse Embryonic Stem Cells. Stem cells. 2002; 20(5): 472-5. [
DOI:10.1634/stemcells.20-5-472]
14. Shabani M, Hemmati S, Hadavi R, Amirghofran Z, Jeddi-Tehrani M, Rabbani H, et al. Optimization of gene transfection in murine myeloma cell lines using different transfection reagents. Avicenna journal of medical biotechnology. 2010; 2(3): 123-30.
15. Salimzadeh L, Jaberipour M, Hosseini A, Ghaderi A. Non-viral transfection methods optimized for gene delivery to a lung cancer cell line. Avicenna journal of medical biotechnology. 2013; 5(2):68-77.
16. Hashemi A, Roohvand F, Ghahremani M, Aghasadeghi M, Vahabpour R, Motevali F, et al. Optimization of transfection methods for Huh-7 and Vero cells: A comparative study. Tsitol Genet. 2012; 46(6): 19-27. [
DOI:10.3103/S0095452712060035]